This segment focuses on the discovery, development, and commercialization of small molecule therapies for various cancers. Research and development activities include identifying and validating novel drug targets, designing and synthesizing small molecule inhibitors and degraders, and conducting preclinical and clinical trials. The company utilizes its protein degradation platform to develop therapies, including BTK degraders (NX-2127, NX-5948) for B-cell malignancies and CBL-B inhibitors (NX-1607) for immuno-oncology indications. Patient impact is addressed by targeting difficult-to-treat cancers, aiming to improve patient outcomes and survival rates. Market positioning is enhanced through strategic collaborations, such as the one with Gilead Sciences. Future opportunities include expanding the pipeline to address additional cancer types and developing combination therapies. Regulatory and clinical aspects involve navigating the FDA approval process and conducting clinical trials to demonstrate safety and efficacy. This segment is a core focus of Nurix's operations, with significant investment in R&D and clinical programs.

This segment concentrates on developing therapies for autoimmune diseases and immune disorders. Research and development efforts are centered on identifying and validating targets within the immune system, designing small molecule inhibitors and degraders, and conducting preclinical and clinical trials. The company leverages its protein degradation platform to develop therapies, including BTK degraders (NX-5948) for autoimmune diseases. The goal is to address unmet medical needs in autoimmune diseases, offering potential for improved patient outcomes and quality of life. Market positioning is strengthened through strategic collaborations. Future opportunities include expanding the pipeline to address additional autoimmune diseases and developing combination therapies. Regulatory and clinical aspects involve navigating the FDA approval process and conducting clinical trials to demonstrate safety and efficacy. This segment is a key area of focus for Nurix, with ongoing research and development efforts.